MedPath
Found 2 clinical trials|View Analysis
Sort by:

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

Phase 3
Recruiting
Conditions
HR+/HER2- Breast Cancer
Advanced Breast Cancer
Interventions
Drug: Apatinib
Drug: CDK4/6 Inhibitor
Drug: Aromatase inhibitor and Fulvestrant
First Posted Date
2024-06-07
Last Posted Date
2024-06-07
Lead Sponsor
Fudan University
Target Recruit Count
184
Registration Number
NCT06447623
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer

Phase 2
Recruiting
Conditions
Breast Cancer
Advanced Breast Cancer
Interventions
Drug: Everolimus 10 mg
Drug: Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors
Drug: CDK4/6 Inhibitor SHR6390
First Posted Date
2023-07-18
Last Posted Date
2024-02-08
Lead Sponsor
Fudan University
Target Recruit Count
265
Registration Number
NCT05949541
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath